Frontier Medicines
PrivateLast Round
Series C
Feb 22, 2024
Total Funding Raised
$235.5M
Company Overview
Frontier Medicines is a clinical-stage biopharmaceutical company that develops precision medicines for genetically-defined patient populations, with a focus on oncology. The company utilizes its proprietary chemoproteomics platform, which integrates covalent drug discovery and machine learning, to discover and develop therapies against disease-causing proteins that were previously considered 'undruggable'. Its lead program, FMC-376, is a novel dual inhibitor that targets both the active and inactive forms of the KRASG12C protein, a mutation found in non-small cell lung, colorectal, and pancreatic cancers. Founded in 2018, the company has established a global partnership with AbbVie to discover and develop novel therapies for oncology and immunology targets.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Precision Medicine, Clinical Trials, Medical AI
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Infrastructure
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Frontier Medicines Comps
Public and private peers based on sector, stage, and business model.
Frontier Medicines Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Feb 22, 2024 | ||||
| Series B | Jul 19, 2021 | ||||
| Series A | Jun 25, 2019 |
Key People
Founding team and executive leadership
Frontier Medicines Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Deerfield Management | Series B, Series C, Series A |
| MPM Capital | Series C, Series B, Series A |
| RA Capital Management | Series C, Series A, Series B |
| DCVC Bio | Series C, Series A |
| Deep Track Capital | Series B |
| MPM BioImpact | Series A |
| Droia Ventures | Series B, Series C, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 31, 2026
Partnered with LG Chem for FMC-220, a p53 activator.
- Mar 17, 2026
Launched the AI-powered Frontier Platform at AACR Annual Meeting 2026.
Frontier Medicines Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Frontier Medicines's valuation, stock price, and market status.
